Alongi, Filippo; Nicosia, Luca; Ricardi, Umberto; Scorsetti, Marta; Greto, Daniela; Balermpas, Panagiotis; Lievens, Yolande; Braam, Pètra; Alicja Jereczek-Fossa, Barbara; Stellamans, Karin; Ratosa, Ivica; Simek, Inga-Malin; Peulen, Heike; Dirix, Piet; Verbeke, Luc; Ramella, Sara; Hemmatazad, Hossein; Khanfir, Kaouthar; Geets, Xavier; Jeene, Paul; ... (2024). Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort. Radiotherapy and oncology, 199, p. 110466. Elsevier 10.1016/j.radonc.2024.110466
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S0167814024007369-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (457kB) |
AIM
To evaluate acute toxicity at 6 months after stereotactic body radiotherapy (SBRT) in patients with oligometastatic cancer within the OligoCare cohort.
MATERIAL AND METHODS
OligoCare is a prospective, registry-based, single-arm, observational study that aims to report prospective real-world data of patients with oligometastases from solid cancer treated with SBRT (NCT03818503). Primary tumor included non-small cell lung cancer (NSCLC), breast cancer (BC), colorectal cancer (CRC), and prostate cancer (PC). This analysis addresses a secondary endpoint of the trial, acute toxicity within 6 months after SBRT.
RESULTS
Out of 1,597registered patients, 1'468 patients were evaluated for acute toxicity. Globally, 290 (20 %) had NSCLC primary disease, 227 (16 %) had BC, 293 (20 %) had CRC, and 658 (45 %) had PC. Concomitant systemic treatment was administered in 527 (35.9 %) patients. According to the EORTC/ESTRO oligometastatic disease (OMD) classification, 828 (56 %) patients had de novo OMD, 464 (32 %) repeat OMD, and 176 (12 %) induced OMD. Acute grade ≥ 3 SBRT related adverse events were reported in 8 (0.5 %) patients, including 2 (0.1 %) fatal AEs. In particular, 6 (0.4 %) grade 3 events were: 1 empyema, 1 pneumonia, 1 radiation pneumonitis, 1 radiation skin injury, 1 decreased appetite, and 1 bone pain. Among those 2 occurred in NSCLC patients, 2 in BC patients, and 1 in CRC and PC patients each. The two (0.1 %) grade 5 toxicity were represented by: pneumonitis and cerebral hemorrhage.
CONCLUSION
OligoCare is the largest prospective registry cohort on oligometastatic disease. Acute toxicity within 6 months was low, confirming the safety of SBRT in the treatment of oligometastases.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology |
UniBE Contributor: |
Hemmatazad, Hossein |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0167-8140 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
14 Aug 2024 11:30 |
Last Modified: |
07 Sep 2024 00:15 |
Publisher DOI: |
10.1016/j.radonc.2024.110466 |
PubMed ID: |
39094630 |
Uncontrolled Keywords: |
Oligometastases SABR SBRT Stereotactic body radiotherapy Toxicity |
BORIS DOI: |
10.48350/199470 |
URI: |
https://boris.unibe.ch/id/eprint/199470 |
Actions (login required)
 |
Edit item |